The remarkable progress in genetics over the last 50 years has led to the development of genetic technologies to identify or alter genes in living organisms, and these technologies can be applied to people. This article presents background information on the role of genetics in human disease, outlines the technologies, and discusses the sources of the strong push for a genetic approach to ill-health and some implications and harmful consequences of using these genetic technologies. The determinants of most diseases are complex and are embedded in a social context. To focus on only one strand of this web—the genetic strand—because it is one that may be amenable to biological/pharmaceutical treatment, although profitable for industry, does not address other important determinants of health and may lead to a harmful overemphasis on genetic approaches. The author outlines some limitations to the potential contribution of genetic technologies to population health across the globe and the need for policy development if these technologies are to have an appropriate place in health care.
Get full access to this article
View all access options for this article.
References
1.
EvansR. G.BarerM. L., and MarmorT. R.Why Are Some People Healthy and Others Not?Aldine de Gruyter, New York, 1994.
2.
BairdP. A., Genetic disorders in children and young adults: A population study. Am. J. Hum. Genet.42: 677–693, 1988.
3.
United Nations Scientific Committee on the Effects of Atomic Radiation.Report: Genetic and Somatic Effects of Ionizing Radiation. New York, 1986.
4.
McKusickV. A.Online Mendelian Inheritance in Man. OMIM (TM) Center for Medical Genetics, Johns Hopkins University, Baltimore, and National Center for Biotechnology Information, National Library of Medicine, Bethesda, Md., 1996. Available from: http://www3.ncbi.nlm.nih.gov/omim/
5.
RennieJ.Grading the gene tests. Sci. Am., June 1994, pp. 88–97.
6.
ErbeR. W., and LevyH. L.Neonatal screening. In Emery and Rimoins's Principles and Practice of Medical Genetics, Ed. 3, edited by RimoinD. L.ConnorJ. M., and PyertizR. E., Vol. 1, Chapt. 29, pp. 581–593. Churchill Livingstone, New York, 1997.
7.
AndrewsL. B.Assessing Genetic Risks: Implications for Health and Social Policy. Committee on Assessing Risks, Division of Health Sciences Policy, Institute of Medicine, National Academy Press, Washington, D.C., 1994.
8.
McCarrickP. M.Genetic testing and genetic screening. Scope Note #22.National Reference Center for Bioethics Literature, Kennedy Institute of Ethics, Washington, D.C., 1993.
9.
Nuffield Council of Bioethics.Genetic Screening: Ethical Issues. London, 1993.
10.
Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Report by the American Society of Human Genetics and the American College of Medical Genetics Boards of Directors. Am. J. Hum. Genet.57: 1233–1241, 1995.
11.
StruewingJ. P., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med.336(20): 1401–1408, 1997.
12.
HubbardR., and LewontinR. C., Pitfalls of genetic testing. N. Engl. J. Med.334(18): 1192–1194, 1996.
13.
PodellR. N.Physician's Guide to Compliance in Hypertension. Merck, West Point, Penn., 1975.
14.
CramerJ. A., How often is medication taken as prescribed?JAMA261: 3273–3277, 1989.
15.
AvornJ., Persistence of use of lipid-lowering medications. JAMA279(18): 1458–1462, 1998.
PincusT., Social conditions and self-management are more powerful determinants of health than access to care. Ann. Intern. Med.129(5): 406–411, 1998.
18.
Genetic testing and insurance.Background statement prepared by The American Society of Human Genetic's Ad Hoc Committee on Genetic Testing/Insurance Issues. Am. J. Hum. Genet.56: 327–331, 1995.
19.
BuchananA., Choosing who will be disabled: Genetic intervention and the morality of inclusion. Soc. Philosophy Policy13(2): 18–46, 1996.
20.
MarteauT., and DrakeH., Attributions for disability: The influence of genetic screening. Soc. Sci. Med.40(8): 1127–1132, 1995.
21.
MahowaldM. B.LevinsonD., and CasselC., The new genetics and women. Milbank Q.74(2): 239–283, 1996.
22.
KitcherP.The Lives to Come. Simon and Schuster, New York, 1996.
23.
TakabayashiH., Development of non-invasive fetal DNA diagnosis from maternal blood. Prenat. Diagn.15: 74–77, 1995.
24.
BairdP. A., Individual interests, societal interests, and reproductive technologies. Perspect. Biol. Med.40(3): 440–451, 1997.
25.
Diagnosis of Genetic Disorders by Amniocentesis During the Second Trimester of Pregnancy.Medical Research Council, Report No. 5. Ottawa, n.d.
26.
An assessment of the hazards of amniocentesis.Report of the Medical Research Council (London) by their Working Party of Amniocentesis. Br. J. Obstet. Gynecol.85(Suppl. 2), 1976.
27.
NICHD, National Registry for Amniocentesis Study Group.Mid-trimester amniocentesis for prenatal diagnosis: Safety and accuracy. JAMA236: 1471–1476, 1976.
28.
ChodirkerB. N., and EvansJ. A.Maternal serum AFP screening programs: The Manitoba experience. In Current Practice of Prenatal Diagnosis Royal Commission on New Reproductive Technologies, Vol. 13, Chapt. 5. Canada Communications Group, Ottawa, 1993.
29.
CunninghamG. C., and KizerK. W., Maternal serum alpha-fetoprotein screening activities of State Health Agencies: A survey. Am. J. Hum. Genet.47: 899–903, 1990.
30.
HoltzmanN. A.Proceed with Caution: Predicting Genetic Risk in the Recombinant DNA Era. Johns Hopkins University Press, Baltimore, 1989.
31.
CarsonS. A., and BusterJ. E., Biopsy of gametes and preimplantation genetic diagnosis. Semin. Reprod. Endocrinol.12(3), 1994.
32.
NeumannP. J.GharibS. D., and WeinsteinM. C., The cost of a successful delivery with in vitro fertilization. N. Engl. J. Med.331(4): 239–243, 1994.
33.
MitchellA.Clinic to sift out bad genes: Prospective parents to pay $6,500– $9,800 to have embryos screened for risk of disease. Globe and Mail, September 24, 1997, p. 1.
34.
BairdP. A., Altering human genes: Social, ethical, and legal implications. Perspect. Biol. Med.37(4): 566–575, 1994.
35.
McCarthyM., Gene therapy applied to treatment of HIV-1 infection. Lancet351: 1709, 1998.
36.
DanksD. M., Germ-line gene therapy: No place in treatment of genetic disease. Editorial. Hum. Gene Ther. 5: 151–152, 1994.
37.
DiekemaD., Is taller really better? Growth hormone therapy in short children. Perspect. Biol. Med.34(1): 109–123, 1990.
38.
LantosJ.SieglerM., and CuttlerL., Ethical issues in growth hormone therapy. JAMA261(7): 1020–1024, 1989.
39.
MurrayT. H., Assessing genetic technologies: Two ethical issues. Int. J. Technol. Assess. Health Care10(4): 573–582, 1994.
40.
WilmutI., Viable offspring derived from fetal and adult mammalian cells. Nature385: 810–813, 1997.
41.
BlumenthalD., Relationships between academic institutions and industry in the life sciences—an industry survey. N. Engl. J. Med.334(6): 368–373, 1996.
42.
CohenJ., Biotechnology: Betting on the genome. Science275: 767–782, 1997.
43.
ShapiroL., Genetics, genomics, and geneconomics: Market forces and natural selection. Presidential address at the American Society of Human Genetics conference, Baltimore. Am. J. Hum. Genet.61(4, Suppl.): 32, 1997.
44.
AbelsonP. H., Biotechnology in a global economy. Science255(5043): 381, 1992.
45.
GolubE. S.Ethical considerations arising from economic aspects of human genetics. In Changing Nature's Course: The Ethical Challenge of Biotechnology, edited by BeckerG. K., in association with BuchananJ. P., Chapt. 6. Hong Kong University Press, Hong Kong, 1996.
46.
HubbardR., and WaldE.Exploding the Gene Myth. Beacon Press, Boston, 1993.
47.
The Future of Medicine: How Genetic Engineering Will Change Us in the Next Century (special issue). Time, January 11, 1999.
48.
LippmanA., Prenatal genetic testing and geneticization: Mother matters for all. Fetal Diagn. Ther.8(Suppl. 1), 175–188, 1993.
49.
Organization for Economic Co-operation and Development.The Global Human Genome Programme. OECD Forum, Paris, 1995.
50.
Cook-DeeganR. M.The human genome project: The formation of federal policies in the United States, 1986–1990. In Bio-Medical Politics, edited by HannaK. E., p. 161. National Academy Press, Washington, D.C., 1991.
51.
KrimskyS.Biotechnics and Society: The Rise of Industrial Genetics. Praeger, New York, 1991.
52.
KoretzG.The unhealthy U.S. income gap. Business Week, November 10, 1997, p. 22.
53.
LynchJ. W., and KaplanG. A., Understanding how inequality in the distribution of income affects health. J. Health Psychol. 2(3): 297–314, 1997.
54.
WilkinsonR. G.Unhealthy Societies: The Afflictions of Inequality. Routledge, London, 1996.
55.
KaplanG. A., Inequality in income and mortality in the United States: Analysis of mortality and potential pathways. BMJ312(7037): 999–1003, 1996.
56.
KawachiI., Social capital, income inequality and mortality. Am. J. Public Health87(9): 1491–1498, 1997.
57.
MoroneJ. A., and MarmorT. R.Representing consumer interests: The case of American health planning. In Citizens and Health Care: Participation and Planning for Social Change, edited by CheckowayB., pp. 39–45. Pergamon Press, New York, 1981.
58.
ShapiroM. F., Regulating pharmaceutical advertising: What will work?Can Med. Assoc. J.156(3): 359–361, 1997.
59.
GaljaardH., Genetic technology in health care: A global view. Int. J. Technol. Assess. Health Care10(4): 527–545, 1994.
60.
ModellB., The ethics of prenatal diagnosis and genetic counselling. World Health Forum11: 179–186, 1990.
61.
AngastiniotisM.KyriakidouS., and HadjiminasM., How thalassaemia was controlled in Cyprus. World Health Forum7: 291–297, 1986.
62.
LoukopoulosD.Prenatal Diagnosis of Thalassaemia and the Hemoglobinopathies, p. 83. CRC Press, Boca Raton, Fla., 1988.
63.
KulievA., Thalassemia can be prevented. World Health Forum7: 286–290, 1986.
64.
U.S. coalition counters breast gene patents.Nature381: 265, 1996.
65.
HoltzmanN. A., and WatsonM. S. (eds.). Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Johns Hopkins University Press, Baltimore, 1998.
66.
KnoppersB. M., and ChadwickR., The Human Genome Project: Under an international ethical microscope. Science265: 2035–2036, 1994.
67.
Guidelines on ethical issues in medical genetics and the provision of genetics services. In World Health Organization, Hereditary Diseases Programme, p. 79. WHO, Geneva, 1995.
68.
MurrayT. H.The genome and access to health care: Two key issues. In The Human Genome Project and the Future of Health Care, edited by MurrayT. H.RothsteinM. A., and MurrayR. F.Jr., pp. 209–223. Indiana University Press, Bloomington, 1996.
